@article{Sciatti_Nesti_Di Lenarda_2021, title={Indirect comparison between ferric carboxymaltose and oral iron replacement in heart failure with reduced ejection fraction: a network meta-analysis}, volume={91}, url={https://www.monaldi-archives.org/macd/article/view/1703}, DOI={10.4081/monaldi.2021.1703}, abstractNote={<p>Treatment of iron deficiency (ID) in patients with heart failure (HF) has improved symptoms, quality of life, exercise capacity and has reduced hospitalizations in randomized controlled trials (RCTs) and meta-analyses. Intravenous ferric carboxymaltose (FCM) provided convincing results in this field, while oral iron supplementation failed. However, FCM and oral iron were compared to placebo, and a comparison between the two strategies is still lacking. We aimed to fill this gap of knowledge with an indirect comparison between them by means of a network meta-analysis of RCTs. Five studies measuring exercise capacity (i.e. 6-minute walking test) and quality of life (i.e. Kansas City Cardiomyopathy Questionnaire) were eligible to be included in our review. Given the limitations of a network meta-analysis, our findings support the better efficacy of FCM than oral iron as regards exercise capacity, with a trend towards an improvement in quality of life, suggesting that FCM seems to be strategy of choice to correct ID in HF patients.</p>}, number={3}, journal={Monaldi Archives for Chest Disease}, author={Sciatti, Edoardo and Nesti, Ugo and Di Lenarda, Andrea}, year={2021}, month={Mar.} }